Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Lunsekimig versus placebo in eosinophilic chronic obstructive pulmonary disease
2024-518016-39-00Phase 3Authorised
- Sponsor
- Sanofi
- Start
- Jul 2026
- Modality
- Nanobodies (VHH) → Antibody Fragments → Engineered Antibody Formats → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 25
01
Overview
Phase 3, randomised, double-blind trial in chronic obstructive pulmonary disease (COPD) comparing Lunsekimig with Placebo (2 arms). Primary endpoint: Annualized rate of moderate to severe chronic obstructive pulmonary disease exacerbations. Planned start Jul 2026; status: authorised.
02
Drugs
lunsekimig
03
Conditions
chronic obstructive pulmonary disease (COPD)
Beyond the preview
Go deeper on 2024-518016-39-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-518016-39-00.